BioCardia (BCDA) announced the first patient enrolled at University of Wisconsin School of Medicine and Public Health in its ongoing Phase 3 CardiAMP HF II clinical trial.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BCDA:
- BioCardia’s CardiAMP Heart Failure II Trial: A Promising Update for Investors
- BioCardia’s Innovative Stem Cell Therapy Trial for Heart Failure: Key Updates and Market Impact
- BioCardia Sets Record Date for Annual Meeting
- BioCardia Regains Nasdaq Compliance, Secures Continued Listing
- BioCardia regains compliance with Nasdaq listing requirements